# Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

> **NCT04603495** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 430 (actual)

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Pelabresib
- **DRUG:** Ruxolitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04603495
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-09
- **Primary completion:** 2023-08-23
- **Final completion:** 2027-06-30
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603495, "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04603495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*